Clinical Trials
We are developing a robust clinical trial program to test the efficacy and safety of our investigative medicines.
| Study | Trial Overview |
|---|---|
|
Program: JANX007 (PSMA x CD3 TRACTr)Status: Active, Recruiting |
The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449. |
|
Program: JANX008 (EGFR x CD3 TRACTr)Status: Active, Recruiting |
The Phase 1 clinical trial is a first-in-human, Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05783622. |
|
Program: JANX011 (CD19 ARM)Status: Active, Recruiting |
A Phase 1, first-in-human, open-label dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JANX011 in healthy adult volunteers. JANX011 is a CD19-targeted Adaptive Immune Response Modulator (ARM) being developed for autoimmune diseases. This study is intended to characterize key immune effects, including B-cell depletion, memory B-cell reset, T-cell expansion, and cytokine release syndrome (CRS) risk to inform subsequent clinical development in autoimmune indications. For additional information about the trial, please visit ClinicalTrials.gov using the identifier NCT07291323. |